Table 2.

Summary of immunologic and clinical data

Patient subject no.Dendritic cell dose (×106)Tumor status at initiation of dendritic cell treatment↑ Systemic CTL activity*TGF-β2 expressionIntracranial T-cell infiltration (post-vaccination)TTP (mo)Overall survival (mo)
11ND+1.68++++18.130.2
21PD5.788.411.4
31ND+0.66+++2738.9
45SD+1.08+++19.935.8
55SD+0.25NANo progression>58.0
65SD+1.89NA14.525.6
710PD5.636.611.9
810SD2.54+16.521.2
910ND+0.32++++28.5>48.4
1010PD3.16NA9.118.0
1110PD2.33NA5.712.0
1210PD6.883.27.3
  • Abbreviations: SD, stable disease; PD, progressive disease; ND, no measurable disease; NA, not available because no surgery was done post-vaccination.

  • * “Positive” CTL response was set as % specific lysis post-vaccine (d 35) >2× magnitude of % specific lysis pre-vaccine (d −14) at two or more E/T ratios.

  • TGF-β2 expression is presented as quantitative units relative to primer controls and normalized to glyceraldehyde-3-phosphate dehydrogenase expression.

  • Scored by semiquantitative assessment of number of CD8+ TILs.